Christopher M Starr

This inventor holds 19 USPTO granted patents and 3 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Enzyme Delivery Systems. Top assignees: Glyko, Inc., Raptor Pharmaceuticals Inc., Biomarin Pharmaceutical Inc.. Active years: 1993-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher M Starr. Retrieved from https://idiyas.com/inventor/christopher-m-starr

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 3)

% Patents Active = 42.1

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 2)

Average Co-Inventor Count = 2.2

ph-index = 8

Forward Citations = 250(Granted Patents)

Company Filing History:

Raptor Pharmaceuticals Inc.

patents

3 out of 137

Biomarin Pharmaceutical Inc.

patents

4. 3 out of 6

Raptor Pharmaceutical Corp

patents

5. 2 out of 2

Bioasis Advanced Technologies Inc.

Years Active: 1993-2020

Loading Chart...

Areas of Expertise:

Enzyme Delivery

Receptor-Associated Protein

Therapeutic Compounds

Cyclic Peptides

Lysosomal Enzymes

Brain Delivery

Active Agents

N-acetylgalactosamine

Recombinant Proteins

Polynucleotides

Fluorophore-Assisted Cloning

Charge-Coupled Devices

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10716862 - Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes (2020-07-21),

2. 9879064 - Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof (2018-01-30),

3. 9062126 - Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof (2015-06-23),

4. 8877714 - Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof (2014-11-04),

5. 8795627 - Treatment of liver disorders by administration of RAP conjugates (2014-08-05),

6. 8609103 - Megalin-based delivery of therapeutic compounds to the brain and other tissues (2013-12-17),

7. 8546319 - Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes (2013-10-01),

8. 8440629 - Cyclic receptor-associated protein (RAP) peptides (2013-05-14),

9. 7829537 - Receptor associated protein (RAP) conjugates (2010-11-09),

10. 7569544 - Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents (2009-08-04),

11. 7560431 - Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents (2009-07-14),

12. 6972124 - Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme (2005-12-06),

13. 6866844 - Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme (2005-03-15),

14. 6569661 - Recombinant &agr;-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof (2003-05-27),

15. 5716508 - Utilization of additives and defined storage systems to increase the (1998-02-10),

Title: **Christopher M. Starr: Innovator in Enzyme Delivery Systems**

Introduction

Christopher M. Starr, based in Sonoma, CA, is a distinguished inventor with a remarkable portfolio consisting of 19 patents. His innovative work primarily focuses on therapeutic applications related to lysosomal storage diseases, showcasing his commitment to advancing medical science and improving patient outcomes.

Latest Patents

Among his latest inventions, one notable patent addresses the use of P97 as an enzyme delivery system for delivering therapeutic lysosomal enzymes. This invention provides compositions and methods for treating, ameliorating, or preventing lysosomal storage diseases by administering a P97 conjugated with an enzyme capable of penetrating lysosomes, even across the blood-brain barrier. Another significant contribution involves compositions comprised of receptor-associated protein (RAP) variants that are specific for CR-containing proteins. This patent details methods for generating receptor-selective RAP variants and outlines their therapeutic applications.

Career Highlights

Christopher has contributed his expertise and innovative spirit to prominent companies in the biotechnology sector. Notable organizations include Glyko, Inc. and Raptor Pharmaceuticals Inc. Through these positions, he has played a crucial role in developing groundbreaking technologies to address critical health issues.

Collaborations

Throughout his career, Christopher has collaborated with esteemed professionals such as Todd C. Zankel and Minmin Qin. These partnerships have further facilitated the exchange of ideas and innovation, amplifying the impact of their collective work in the field.

Conclusion

Christopher M. Starr is a testament to the power of innovation in biotechnology. With his extensive portfolio and impactful collaborations, he continues to drive advancements in therapeutic solutions, positioning himself as a leading figure in the realm of medical inventions. His work not only reflects his ingenuity but also his dedication to enhancing the quality of life for patients affected by lysosomal storage diseases.

Profile summary based on public USPTO records.